☆ 4.6 Article

Predictive Value of Clinicopathological Factors to Guide Post-Operative Radiotherapy in Completely Resected pN2-Stage III Non-Small Cell Lung Cancer

DIAGNOSTICS (2023)

Related references

Note: Only part of the references are listed.

Article Radiology, Nuclear Medicine & Medical Imaging

Uncertain resection of highest mediastinal lymph node positive among pN2 non-small cell lung cancer patients: survival analysis of postoperative radiotherapy and driver gene mutations

Qianyue Deng et al.

Summary: This study evaluated the effect of postoperative radiotherapy on the survival of patients with high mediastinal lymph node positive pN2 NSCLC. The results showed that postoperative radiotherapy can significantly improve locoregional recurrence-free and disease-free survival, while driver gene mutation status has a significant impact on overall survival.

JAPANESE JOURNAL OF RADIOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

The impact of postoperative radiotherapy on the survival of patients with stage III non-small cell lung cancer: A CONSORT-compliant analysis using the SEER database

Kun Wu et al.

Summary: This retrospective cohort study investigated the impact of postoperative radiotherapy (PORT) on overall survival (OS) in patients with resected stage III non-small cell lung cancer (NSCLC). The study found that, overall, PORT did not significantly affect OS. However, subgroup analysis showed that certain patient subgroups, such as those with stage IIIA/N2, stage IIIB, squamous cell carcinoma, tumor grade III-IV, or lymph node ratio (LNR) > 1/3, may benefit from PORT in terms of improved OS.

MEDICINE (2023)

Add to Collection

Review Oncology

Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer

Antonin Levy et al.

Summary: Patients with locally advanced resected non-small-cell lung cancer have a high risk of relapse. The use of postoperative radiation therapy (PORT) has been controversial, and its role in patients with incomplete resection and completely resected cancer is still not well-defined.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial

Cecile Le Pechoux et al.

Summary: This study aimed to investigate whether three-dimensional conformal radiotherapy (3D PORT) should be part of the standard treatment for patients with non-small-cell lung cancer (NSCLC) with N2 involvement. The results showed that 3-year disease-free survival was slightly higher in patients with PORT compared to those without, but the difference was not significant.

LANCET ONCOLOGY (2022)

Add to Collection

Review Genetics & Heredity

Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis

Barbara Melosky et al.

Summary: This meta-analysis provides a worldwide overview of EGFR mutation prevalence in NSCLC patients and identifies important covariates that influence EGFR mutation status, emphasizing the importance of global testing for appropriate targeted treatment decisions.

MOLECULAR DIAGNOSIS & THERAPY (2022)

Add to Collection

Review Surgery

Lung Cancer Epidemiology and Screening

Aundrea L. Oliver

Summary: Lung cancer remains the most lethal cancer worldwide, particularly in Asia where the largest population resides. Factors such as asbestos, radon, and tobacco smoking contribute to the increasing rates of lung cancer. Liquid biopsy shows promise as a noninvasive diagnostic and monitoring tool in lung cancer.

SURGICAL CLINICS OF NORTH AMERICA (2022)

Add to Collection

Article Oncology

Optimal positive lymph node ratio showing the benefit of postoperative radiotherapy in pathologic N2 non-small cell lung cancer: an exploratory study using the Surveillance, Epidemiology, and End Results data

Shiho Lee et al.

Summary: This study used the SEER data to analyze the clinical parameters and efficacy of postoperative radiotherapy (PORT) in patients with pN2 non-small cell lung cancer (NSCLC), and found that a specific range of lymph node ratios could maximize the survival benefit of radiation therapy.

RADIATION ONCOLOGY JOURNAL (2022)

Add to Collection

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

Add to Collection

Review Biochemistry & Molecular Biology

The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines

Alireza Mardanshahi et al.

Summary: Radiotherapy is a common cancer treatment modality that can activate the PI3K and AKT signaling pathway to enhance tumor cell radiosensitivity. By inhibiting downstream mediators like mTOR, combined with radiation, can increase malignant cell radiosensitivity through autophagy activation.

MOLECULAR BIOLOGY REPORTS (2021)

Add to Collection

Article Oncology

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy The Phase 3 PORT-C Randomized Clinical Trial

Zhouguang Hui et al.

Summary: The study evaluated the impact of postoperative radiotherapy (PORT) on survival and safety in patients with pIIIA-N2 non-small cell lung cancer. The results showed that PORT did not improve disease-free survival but helped reduce local recurrence.

JAMA ONCOLOGY (2021)

Add to Collection

Editorial Material Oncology

Complete Resection in Lung Cancer Surgery: From Definition to Validation and Beyond

Ramon Rami-Porta et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Postoperative radiotherapy option based on mediastinal lymph node reclassification for patients with pN2 non-small-cell lung cancer

J. Jin et al.

CURRENT ONCOLOGY (2020)

Add to Collection

Article Oncology

The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-small cell lung cancer

Chongze Yuan et al.

JOURNAL OF SURGICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Lymphovascular Invasion Increases the Risk of Nodal and Distant Recurrence in Node-Negative Stage I-IIA Non-Small-Cell Lung Cancer

Soo Yoon Sung et al.

ONCOLOGY (2018)

Add to Collection

Article Oncology

Survival Patterns for Patients with Resected N2 Non-Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach

Weiye Deng et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

Add to Collection

Article Oncology

Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number

Siwei Wang et al.

RADIATION ONCOLOGY (2017)

Add to Collection

Review Oncology

Postoperative radiotherapy for lung cancer: Is it worth the controversy?

Charlotte Billiet et al.

CANCER TREATMENT REVIEWS (2016)

Add to Collection

Article

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

Yue-Lun Zhang et al.

Oncotarget (2016)

Add to Collection

Article Oncology

Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection

Changhoon Yoo et al.

CLINICAL LUNG CANCER (2015)

Add to Collection

Article Oncology

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non-Small-Cell Lung Cancer

Damien Urban et al.

JOURNAL OF THORACIC ONCOLOGY (2013)

Add to Collection

Article

East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians

Wei Zhou et al.

Chinese Journal of Cancer (2011)

Add to Collection

Article Oncology

Prognostic Factors for Resected Non-Small Cell Lung Cancer with pN2 Status: Implications for Use of Postoperative Radiotherapy

Luigi Moretti et al.

ONCOLOGIST (2009)

Add to Collection

Article Oncology

Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group

Jean-Pierre Pignon et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Oncology

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials

DW Bell et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

Article Oncology

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

DA Eberhard et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.